[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chiesi Poland Sp. z o.o.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":86},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100580143","tacrolimus-and-risk-factors-for-glucose-metabolism-disorders-in-kidney-transplant-patients-100580143",false,"NCT06833463","Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients","TARGET","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Recipients of a kidney transplant from a living or deceased donor\n* Standard immunosuppressive regimen post-kidney transplantation (KTx) including Envarsus®\n* LCP Tacrolimus therapy initiated from the day of KTx or conversion from another tacrolimus formulation to LCP Tacrolimus by day 8 at the latest, according to the institution's routine practice\n* Informed patient consent to participate in the study\n\nExclusion Criteria:\n\n* Diagnosis of diabetes (type 1 or type 2) treated with diet or glucose-lowering drugs\n* Random glycemia\u002FHbA1c levels justifying a diagnosis of diabetes at the time of study enrollment\n* Kidney retransplantation\n* Recipients of a multi-organ transplant\n* Use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss\n* Use of flozins for renal or cardiac indications\n* Chronic use of drugs affecting carbohydrate metabolism, such as glucocorticosteroids","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","Many people who receive a kidney transplant develop problems with how their body processes sugar (glucose). This includes conditions like prediabetes and diabetes, which can lead to more health issues, such as heart problems and infections.\n\nOne of the main medications used after a kidney transplant, called tacrolimus, can contribute to these sugar problems. Tacrolimus helps protect the new kidney, but it can also harm the cells in the pancreas that produce insulin, a hormone that controls blood sugar. Other factors, such as stress on the body and insulin resistance, can make things worse.\n\nThe effect of tacrolimus on blood sugar may depend on how the body processes the drug. Some people break down tacrolimus quickly (fast metabolizers), so they need higher doses to reach the right level in their blood. Others break it down more slowly (slow metabolizers) and require lower doses. Doctors can measure how fast someone metabolizes tacrolimus using aparameter called the concentration-to-dose (C\u002FD) ratio.\n\nThis study aims to find out what increases the risk of developing blood sugar problems after a kidney transplant. It will focus on how quickly patients process tacrolimus and whether this affects their risk of developing diabetes. The study will also look at how common these issues are in kidney transplant patients in Poland.",[24],"Kidney Transplant","RECRUITING","2026-04-01",{"date":28,"type":29},"2026-04-02","ACTUAL",{"date":31,"type":29},"2025-05-29",{"date":33,"type":20},"2028-01-30",{"name":35,"class":36},"Chiesi Poland Sp. z o.o.","INDUSTRY",6,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":48,"conditions":49,"keywords":52,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100598336","bedside-ultrasound-to-monitor-lung-function-and-blood-flow-in-newborns-treated-with-surfactant-100598336","NCT07070167","Bedside Ultrasound to Monitor Lung Function and Blood Flow in Newborns Treated With Surfactant","Point-of-Care Ultrasonography for Assessing Lung Aeration and Pulmonary Vascular Resistance Dynamics After Surfactant Administration in Neonates With Respiratory Distress Syndrome","ULISSES","Inclusion Criteria:\n\n* Preterm neonates (gestational age \\\u003C37 weeks) with established Respiratory Distress Syndrome (RDS) or at risk for RDS\n* Decision of the use of surfactant by the attending physician\n\nExclusion Criteria:\n\n* Presence of major congenital abnormalities of the respiratory system\n* Infants requiring primary intubation and mechanical ventilation in the delivery room",{"count":47,"type":20},200,"The ULISSES study looks at how doctors use bedside ultrasound to help treat premature babies with breathing problems caused by Respiratory Distress Syndrome (RDS). It focuses on whether doctors decide to give a medicine called surfactant based on oxygen levels alone or if they also use lung ultrasound images to guide their decision.\n\nAround 200 babies will take part in the study in hospitals across Poland. Doctors will do ultrasound scans of the babies' lungs before and after surfactant is given. In some hospitals, heart and lung blood flow will also be checked to look for signs of high blood pressure in the lungs.\n\nThe study will see if both lungs improve equally after treatment or if one side stays worse, and whether this affects how much breathing support the baby needs. The results may help doctors improve how and when they give surfactant, leading to better care for newborns with RDS.",[50,51],"Lung Ultrasound","Respiratory Distress Syndrome, Newborn",[53],"surfactant","NOT_YET_RECRUITING","2025-07-15",{"date":57,"type":29},"2025-07-17",{"date":59,"type":20},"2025-08-30",{"date":61,"type":20},"2026-12-30",{"name":35,"class":36},2,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100559733","trimaximize-a-multicentre-prospective-non-interventional-trial-in-asthma-patients-100559733","NCT06567977","TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients","TriMaximize: A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS\u002FLABA\u002FLAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes.","Trimaximize PL","Inclusion Criteria:\n\n* Patients ≥ 18 years of age,\n* Patients with confirmed leading diagnosis of asthma with or without concomitant COPD,\n* Physician decision to start fixed triple therapy with ICS\u002FLABA\u002FLAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS,\n* Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study.\n\nExclusion Criteria:\n\n• Participation in an interventional clinical trial within 30 days prior to en-rolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.",{"count":73,"type":20},60,"TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS\u002FLABA\u002FLAMA single-inhaler triple therapy in a real-world setting and characterizing the effects on health-related outcomes.",[76],"Asthma","2024-08-20",{"date":79,"type":29},"2024-08-23",{"date":81,"type":20},"2024-08",{"date":83,"type":20},"2025-08-01",{"name":35,"class":36},1,""]